The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Multiple Myeloma trial highlights: ARROW, OPTIMISMM & ALCYONE
The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data from their recent clinical trials. In this video, Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, speaks about his highlights for multiple myeloma (MM), giving a critical overview of the data and their implications for the future of MM care. He includes: ARROW (NCT02412878), which has demonstrated that carfilzomib has a PFS benefit in once-weekly vs. twice-weekly dosing; OPTIMISMM (NCT01734928), which reported a PFS benefit from pomalidomide, bortezomib and dexamethasone in the relapsed/refractory setting; and a sub-group analysis of ALCYONE (NCT02195479), which showed that the quartet therapy of daratumumab plus bortezomib, melphalan and prednisone (VMP) is more effective in elderly patients than VMP alone.
